Covered recipient · General Payments record
EMMANUEL JEAN-MARIE MIGNOT
Allopathic & Osteopathic Physicians Psychiatry & Neurology Sleep Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$23,131.44
17 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $17,302.50 | 6 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,000.00 | 1 |
| Travel and Lodging | $489.35 | 3 |
| Food and Beverage | $339.59 | 7 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $11,052.50 | 4 |
| Eisai Inc. | $10,728.94 | 12 |
| HARMONY BIOSCIENCES LLC | $1,350.00 | 1 |
Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
EMMANUEL JEAN-MARIE MIGNOT
NPI 1023151800 · CMS profile ID 961917
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Sleep Medicine
STANFORD, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1023151800?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023151800?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023151800?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1023151800?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
17 matching records · $23,131.44 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–17 of 17.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| HARMONY BIOSCIENCES LLC | $1,350.00 | 12/02/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853088107 | CMS |
| Eisai Inc. | $2,970.00 | 10/21/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833765741 | CMS |
| Eisai Inc. | $6,930.00 | 10/21/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833765751 | CMS |
| Eisai Inc. | $115.41 | 10/21/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845769975 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,452.50 | 10/01/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820087601 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,600.00 | 09/20/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820087597 | CMS |
| Eisai Inc. | $213.04 | 08/14/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833772433 | CMS |
| Eisai Inc. | $50.00 | 08/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833772439 | CMS |
| Eisai Inc. | $12.50 | 08/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833772443 | CMS |
| Eisai Inc. | $12.50 | 08/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833772449 | CMS |
| Eisai Inc. | $160.90 | 08/14/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833772455 | CMS |
| Eisai Inc. | $50.00 | 08/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833779961 | CMS |
| Eisai Inc. | $73.58 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833772845 | CMS |
| Eisai Inc. | $43.32 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833780049 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 07/08/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820087594 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,000.00 | 06/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820087591 | CMS |
| Eisai Inc. | $97.69 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833771621 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $992.00 | 1 |
| PY2025 | Principal investigator | $2,401,878.07 | 533 |
| PY2024 | Principal investigator | $1,022,037.24 | 254 |
| PY2023 | Principal investigator | $275,388.22 | 59 |
| PY2022 | Principal investigator | $175,960.37 | 12 |
| PY2021 | Principal investigator | $361,355.25 | 19 |
| PY2020 | Recipient | $3,276.62 | 36 |
| PY2020 | Principal investigator | $214,065.50 | 29 |
| PY2019 | Recipient | $921.37 | 2 |
| PY2019 | Principal investigator | $67,788.78 | 53 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
534 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Alkermes, Inc. | $444.00 | 12/24/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615581 |
| Principal investigator 1 | Alkermes, Inc. | $1,092.00 | 12/24/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617965 |
| Principal investigator 1 | Alkermes, Inc. | $670.00 | 12/24/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619411 |
| Principal investigator 1 | Alkermes, Inc. | $6,924.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613047 |
| Principal investigator 1 | Alkermes, Inc. | $70.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614198 |
| Principal investigator 1 | Alkermes, Inc. | $7,043.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615025 |
| Principal investigator 1 | Alkermes, Inc. | $4,294.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616505 |
| Principal investigator 1 | Alkermes, Inc. | $4,393.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618461 |
| Principal investigator 1 | Alkermes, Inc. | $1,792.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618705 |
| Principal investigator 1 | Alkermes, Inc. | $2,066.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208620580 |
| Principal investigator 1 | Alkermes, Inc. | $4,381.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621398 |
| Principal investigator 1 | Alkermes, Inc. | $4,634.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622255 |
| Principal investigator 1 | Alkermes, Inc. | $7,704.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624512 |
| Principal investigator 1 | Alkermes, Inc. | $7,443.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624925 |
| Principal investigator 1 | Alkermes, Inc. | $3,000.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625385 |
| Principal investigator 1 | Alkermes, Inc. | $7,434.00 | 12/23/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625876 |
| Principal investigator 1 | Alkermes, Inc. | $1,607.00 | 12/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613896 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 12/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208614134 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 12/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616511 |
| Principal investigator 1 | Alkermes, Inc. | $4,471.00 | 12/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616513 |
| Principal investigator 1 | Alkermes, Inc. | $6,373.00 | 12/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617129 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 12/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620127 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 12/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620586 |
| Principal investigator 1 | Alkermes, Inc. | $7,660.00 | 12/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622059 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 12/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623826 |
| Principal investigator 1 | Alkermes, Inc. | $79.50 | 12/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622337 |
| Principal investigator 1 | Alkermes, Inc. | $18.80 | 12/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625223 |
| Principal investigator 1 | Alkermes, Inc. | $131.60 | 12/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625225 |
| Principal investigator 1 | Alkermes, Inc. | $13.25 | 12/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625698 |
| Principal investigator 1 | Alkermes, Inc. | $71.60 | 12/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625920 |
| Principal investigator 1 | Alkermes, Inc. | $95.76 | 12/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615659 |
| Principal investigator 1 | Alkermes, Inc. | $1,038.16 | 12/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626516 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1.98 | 11/24/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744361 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5.76 | 11/24/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744363 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $9.03 | 11/24/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744365 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $0.99 | 11/24/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744367 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $60.20 | 11/24/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744369 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1.65 | 11/24/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744371 |
| Principal investigator 1 | Alkermes, Inc. | $4,393.00 | 11/19/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613045 |
| Principal investigator 1 | Alkermes, Inc. | $4,381.00 | 11/19/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613685 |
| Principal investigator 1 | Alkermes, Inc. | $7,043.00 | 11/19/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615573 |
| Principal investigator 1 | Alkermes, Inc. | $2,066.00 | 11/19/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616267 |
| Principal investigator 1 | Alkermes, Inc. | $1,792.00 | 11/19/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616899 |
| Principal investigator 1 | Alkermes, Inc. | $7,434.00 | 11/19/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208617727 |
| Principal investigator 1 | Alkermes, Inc. | $6,924.00 | 11/19/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624308 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $60,532.94 | 11/19/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223269364 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,100.00 | 11/12/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269346 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,536.00 | 11/12/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269348 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,162.00 | 11/12/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269350 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,950.00 | 11/12/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269352 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,485.00 | 11/12/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269354 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,760.00 | 11/12/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269356 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,280.00 | 11/12/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269358 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,060.00 | 11/12/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269360 |
| Principal investigator 1 | Alkermes, Inc. | $7,660.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616043 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616685 |
| Principal investigator 1 | Alkermes, Inc. | $5,008.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618467 |
| Principal investigator 1 | Alkermes, Inc. | $1,607.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620584 |
| Principal investigator 1 | Alkermes, Inc. | $6,373.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622685 |
| Principal investigator 1 | Alkermes, Inc. | $4,471.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623824 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624720 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624722 |
| Principal investigator 1 | Alkermes, Inc. | $4,397.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625163 |
| Principal investigator 1 | Alkermes, Inc. | $4,471.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625393 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625395 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626044 |
| Principal investigator 1 | Alkermes, Inc. | $4,471.00 | 11/10/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626664 |
| Principal investigator 1 | Alkermes, Inc. | $191.52 | 11/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622331 |
| Principal investigator 1 | Alkermes, Inc. | $53.00 | 11/05/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625926 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $70,410.24 | 10/29/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223269338 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 10/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613998 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 10/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622141 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 10/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625243 |
| Principal investigator 1 | Alkermes, Inc. | $5,504.00 | 10/13/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614803 |
| Principal investigator 1 | Alkermes, Inc. | $1,250.00 | 10/13/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619657 |
| Principal investigator 1 | Alkermes, Inc. | $3,584.00 | 10/13/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622493 |
| Principal investigator 1 | Alkermes, Inc. | $20,721.00 | 10/13/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623166 |
| Principal investigator 1 | Alkermes, Inc. | $3,840.00 | 10/13/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624726 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 10/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615583 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 10/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619415 |
| Principal investigator 1 | Alkermes, Inc. | $5,008.00 | 10/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620125 |
| Principal investigator 1 | Alkermes, Inc. | $4,397.00 | 10/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623822 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 10/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624062 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 10/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624718 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 10/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624927 |
| Principal investigator 1 | Alkermes, Inc. | $129.77 | 10/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208614623 |
| Principal investigator 1 | Alkermes, Inc. | $1,879.00 | 10/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615389 |
| Principal investigator 1 | Alkermes, Inc. | $389.31 | 10/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616559 |
| Principal investigator 1 | Alkermes, Inc. | $18,115.00 | 10/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621612 |
| Principal investigator 1 | Alkermes, Inc. | $5,000.00 | 10/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622259 |
| Principal investigator 1 | Alkermes, Inc. | $3,840.00 | 10/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623632 |
| Principal investigator 1 | Alkermes, Inc. | $1,250.00 | 10/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625638 |
| Principal investigator 1 | Alkermes, Inc. | $3,200.00 | 10/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626896 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $211.20 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269288 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,298.48 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269290 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,586.42 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269292 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $29,516.16 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269294 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269300 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269302 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269304 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269306 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269308 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269310 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269312 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269314 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269316 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269318 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269320 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269322 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269324 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269326 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269328 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269330 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269332 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,154.50 | 10/01/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269334 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 09/29/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625493 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $31,663.00 | 09/26/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | No dispute reported | 06/30/2026 | 1223269280 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,504.00 | 09/26/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | No dispute reported | 06/30/2026 | 1223269282 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,584.00 | 09/26/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | No dispute reported | 06/30/2026 | 1223269284 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,040.00 | 09/26/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | No dispute reported | 06/30/2026 | 1223269286 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $60,738.28 | 09/24/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223269276 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,551.97 | 09/24/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223269278 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208614268 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208614733 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617453 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617873 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618849 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620702 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620916 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621132 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621534 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623556 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625089 |
| Principal investigator 1 | Alkermes, Inc. | $4,760.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626118 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626588 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 09/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626808 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,610.88 | 09/12/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269274 |
| Principal investigator 1 | Alkermes, Inc. | $4,471.00 | 09/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613353 |
| Principal investigator 1 | Alkermes, Inc. | $2,377.00 | 09/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208614218 |
| Principal investigator 1 | Alkermes, Inc. | $4,397.00 | 09/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615293 |
| Principal investigator 1 | Alkermes, Inc. | $4,397.00 | 09/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615935 |
| Principal investigator 1 | Alkermes, Inc. | $2,377.00 | 09/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618069 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 09/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620876 |
| Principal investigator 1 | Alkermes, Inc. | $3,165.00 | 09/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622575 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 09/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624600 |
| Principal investigator 1 | Alkermes, Inc. | $4,397.00 | 09/08/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625257 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,696.00 | 09/04/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737601 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,895.00 | 09/04/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737603 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,500.00 | 09/04/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737605 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,280.00 | 09/04/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737609 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,920.00 | 09/04/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737617 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,221.00 | 09/04/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737623 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,738.00 | 09/04/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737639 |
| Principal investigator 1 | Alkermes, Inc. | $172.25 | 09/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613772 |
| Principal investigator 1 | Alkermes, Inc. | $51.75 | 09/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614899 |
| Principal investigator 1 | Alkermes, Inc. | $131.60 | 09/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619035 |
| Principal investigator 1 | Alkermes, Inc. | $71.60 | 09/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619781 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5,794.05 | 08/21/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737611 |
| Principal investigator 1 | Alkermes, Inc. | $70.00 | 08/13/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618297 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,274.05 | 08/13/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737615 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,496.00 | 08/13/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737625 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $18,120.96 | 08/13/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737635 |
| Principal investigator 1 | Alkermes, Inc. | $4,289.00 | 08/11/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613357 |
| Principal investigator 1 | Alkermes, Inc. | $6,196.00 | 08/11/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618807 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613145 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615697 |
| Principal investigator 1 | Alkermes, Inc. | $2,377.00 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615707 |
| Principal investigator 1 | Alkermes, Inc. | $2,377.00 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616131 |
| Principal investigator 1 | Alkermes, Inc. | $4,397.00 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616773 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618067 |
| Principal investigator 1 | Alkermes, Inc. | $136.80 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618327 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620217 |
| Principal investigator 1 | Alkermes, Inc. | $2,377.00 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620453 |
| Principal investigator 1 | Alkermes, Inc. | $1,364.00 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620878 |
| Principal investigator 1 | Alkermes, Inc. | $4,471.00 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621092 |
| Principal investigator 1 | Alkermes, Inc. | $4,397.00 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623926 |
| Principal investigator 1 | Alkermes, Inc. | $1,505.00 | 08/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625501 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 08/05/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208614663 |
| Principal investigator 1 | Alkermes, Inc. | $51.40 | 08/05/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618305 |
| Principal investigator 1 | Alkermes, Inc. | $3,165.00 | 08/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617617 |
| Principal investigator 1 | Alkermes, Inc. | $758.00 | 08/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618575 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 08/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618577 |
| Principal investigator 1 | Alkermes, Inc. | $3,114.00 | 08/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621698 |
| Principal investigator 1 | Alkermes, Inc. | $3,114.00 | 08/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626124 |
| Principal investigator 1 | Alkermes, Inc. | $3,165.00 | 08/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626126 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $599.04 | 07/28/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737599 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,836.80 | 07/28/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737607 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $8,417.28 | 07/28/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737613 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $424.96 | 07/28/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737619 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,766.40 | 07/28/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737621 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $9,520.64 | 07/28/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737627 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $125.44 | 07/28/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737629 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $373.76 | 07/28/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737631 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $440.32 | 07/28/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737633 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,556.48 | 07/28/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737637 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $921.60 | 07/28/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737641 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5,152.00 | 07/28/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737643 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 07/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208612919 |
| Principal investigator 1 | Alkermes, Inc. | $6,794.00 | 07/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614440 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 07/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614659 |
| Principal investigator 1 | Alkermes, Inc. | $6,993.00 | 07/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616385 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 07/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617827 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 07/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618799 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 07/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619027 |
| Principal investigator 1 | Alkermes, Inc. | $6,196.00 | 07/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620449 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 07/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622157 |
| Principal investigator 1 | Alkermes, Inc. | $4,289.00 | 07/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625041 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 07/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625936 |
| Principal investigator 1 | Alkermes, Inc. | $3,500.00 | 07/16/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626344 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $204,791.04 | 07/16/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269244 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $28,301.00 | 07/11/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223269238 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,504.00 | 07/11/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223269240 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,424.00 | 07/11/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223269242 |
| Principal investigator 1 | Alkermes, Inc. | $5,949.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613147 |
| Principal investigator 1 | Alkermes, Inc. | $6,118.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208614446 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208614661 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208614889 |
| Principal investigator 1 | Alkermes, Inc. | $1,492.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615113 |
| Principal investigator 1 | Alkermes, Inc. | $6,118.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616129 |
| Principal investigator 1 | Alkermes, Inc. | $3,114.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616585 |
| Principal investigator 1 | Alkermes, Inc. | $3,165.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617427 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618583 |
| Principal investigator 1 | Alkermes, Inc. | $1,492.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621288 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623712 |
| Principal investigator 1 | Alkermes, Inc. | $4,151.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625505 |
| Principal investigator 1 | Alkermes, Inc. | $5,949.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625726 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 07/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626762 |
| Principal investigator 1 | Eisai Inc. | $16,795.91 | 07/01/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | Lemborexant in Delayed Sleep Phase Syndrome | No dispute reported | 06/30/2026 | 1244561338 |
| Principal investigator 1 | Alkermes, Inc. | $33.32 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208612993 |
| Principal investigator 1 | Alkermes, Inc. | $74.80 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613331 |
| Principal investigator 1 | Alkermes, Inc. | $12.06 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613543 |
| Principal investigator 1 | Alkermes, Inc. | $75.00 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613822 |
| Principal investigator 1 | Alkermes, Inc. | $43.12 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614016 |
| Principal investigator 1 | Alkermes, Inc. | $5.95 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614074 |
| Principal investigator 1 | Alkermes, Inc. | $200.20 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614278 |
| Principal investigator 1 | Alkermes, Inc. | $1,879.00 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614368 |
| Principal investigator 1 | Alkermes, Inc. | $12.06 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615115 |
| Principal investigator 1 | Alkermes, Inc. | $74.24 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615503 |
| Principal investigator 1 | Alkermes, Inc. | $51.55 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615773 |
| Principal investigator 1 | Alkermes, Inc. | $32.70 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616197 |
| Principal investigator 1 | Alkermes, Inc. | $1.74 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616381 |
| Principal investigator 1 | Alkermes, Inc. | $3,200.00 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616537 |
| Principal investigator 1 | Alkermes, Inc. | $16.00 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616619 |
| Principal investigator 1 | Alkermes, Inc. | $154.20 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617271 |
| Principal investigator 1 | Alkermes, Inc. | $1.74 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617407 |
| Principal investigator 1 | Alkermes, Inc. | $192.75 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618143 |
| Principal investigator 1 | Alkermes, Inc. | $3,840.00 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618241 |
| Principal investigator 1 | Alkermes, Inc. | $7.35 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618395 |
| Principal investigator 1 | Alkermes, Inc. | $5,000.00 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618435 |
| Principal investigator 1 | Alkermes, Inc. | $34.35 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618653 |
| Principal investigator 1 | Alkermes, Inc. | $1.74 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619261 |
| Principal investigator 1 | Alkermes, Inc. | $3,584.00 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620367 |
| Principal investigator 1 | Alkermes, Inc. | $20,460.00 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620814 |
| Principal investigator 1 | Alkermes, Inc. | $17.10 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621072 |
| Principal investigator 1 | Alkermes, Inc. | $27.82 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621354 |
| Principal investigator 1 | Alkermes, Inc. | $127.40 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621981 |
| Principal investigator 1 | Alkermes, Inc. | $23.54 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622441 |
| Principal investigator 1 | Alkermes, Inc. | $50.15 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624234 |
| Principal investigator 1 | Alkermes, Inc. | $74.24 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624448 |
| Principal investigator 1 | Alkermes, Inc. | $74.24 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624887 |
| Principal investigator 1 | Alkermes, Inc. | $162.05 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625025 |
| Principal investigator 1 | Alkermes, Inc. | $32.10 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625339 |
| Principal investigator 1 | Alkermes, Inc. | $24.12 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625940 |
| Principal investigator 1 | Alkermes, Inc. | $192.75 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625990 |
| Principal investigator 1 | Alkermes, Inc. | $25.00 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626006 |
| Principal investigator 1 | Alkermes, Inc. | $7.70 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626216 |
| Principal investigator 1 | Alkermes, Inc. | $145.60 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626372 |
| Principal investigator 1 | Alkermes, Inc. | $1,250.00 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626534 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,958.40 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223281610 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $366.08 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223281612 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,280.00 | 06/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223281614 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,848.00 | 06/13/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737577 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $924.00 | 06/13/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737581 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,500.00 | 06/13/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737587 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,895.00 | 06/13/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737589 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5,750.00 | 06/13/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737591 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6,500.00 | 06/13/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737593 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,738.00 | 06/13/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737595 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,500.00 | 06/13/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737597 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/11/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613711 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/11/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614154 |
| Principal investigator 1 | Alkermes, Inc. | $6,990.00 | 06/11/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616933 |
| Principal investigator 1 | Alkermes, Inc. | $4,157.00 | 06/11/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621232 |
| Principal investigator 1 | Alkermes, Inc. | $6,794.00 | 06/11/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624951 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/11/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626286 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $0.96 | 06/11/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744355 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6.72 | 06/11/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744357 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $16.05 | 06/11/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744359 |
| Principal investigator 1 | Alkermes, Inc. | $758.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613647 |
| Principal investigator 1 | Alkermes, Inc. | $3,201.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613872 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613878 |
| Principal investigator 1 | Alkermes, Inc. | $1,492.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208614773 |
| Principal investigator 1 | Alkermes, Inc. | $1,492.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615001 |
| Principal investigator 1 | Alkermes, Inc. | $5,949.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615549 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615793 |
| Principal investigator 1 | Alkermes, Inc. | $3,114.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616253 |
| Principal investigator 1 | Alkermes, Inc. | $5,947.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616481 |
| Principal investigator 1 | Alkermes, Inc. | $4,600.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616887 |
| Principal investigator 1 | Alkermes, Inc. | $1,492.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617105 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617513 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617697 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617705 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618193 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618685 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618691 |
| Principal investigator 1 | Alkermes, Inc. | $758.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618903 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619377 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619861 |
| Principal investigator 1 | Alkermes, Inc. | $5,947.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620107 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620554 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620762 |
| Principal investigator 1 | Alkermes, Inc. | $6,118.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621382 |
| Principal investigator 1 | Alkermes, Inc. | $3,201.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621586 |
| Principal investigator 1 | Alkermes, Inc. | $3,201.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621815 |
| Principal investigator 1 | Alkermes, Inc. | $5,947.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622233 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622471 |
| Principal investigator 1 | Alkermes, Inc. | $1,492.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622651 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622661 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622663 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623130 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623798 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624278 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624482 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624498 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624911 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625375 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625617 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626024 |
| Principal investigator 1 | Alkermes, Inc. | $3,165.00 | 06/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626234 |
| Principal investigator 1 | Alkermes, Inc. | $26.21 | 06/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619173 |
| Principal investigator 1 | Alkermes, Inc. | $13.79 | 06/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619407 |
| Principal investigator 1 | Alkermes, Inc. | $135.00 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613351 |
| Principal investigator 1 | Alkermes, Inc. | $35.00 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616123 |
| Principal investigator 1 | Alkermes, Inc. | $135.00 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616379 |
| Principal investigator 1 | Alkermes, Inc. | $11.02 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208617963 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618065 |
| Principal investigator 1 | Alkermes, Inc. | $220.78 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618565 |
| Principal investigator 1 | Alkermes, Inc. | $35.00 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619753 |
| Principal investigator 1 | Alkermes, Inc. | $30.52 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208620335 |
| Principal investigator 1 | Alkermes, Inc. | $10.00 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208620774 |
| Principal investigator 1 | Alkermes, Inc. | $341.02 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208620870 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621284 |
| Principal investigator 1 | Alkermes, Inc. | $341.02 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622359 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622775 |
| Principal investigator 1 | Alkermes, Inc. | $220.78 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622777 |
| Principal investigator 1 | Alkermes, Inc. | $7.45 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622920 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623276 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624602 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625035 |
| Principal investigator 1 | Alkermes, Inc. | $8.33 | 06/06/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626432 |
| Principal investigator 1 | Alkermes, Inc. | $20,721.00 | 06/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615555 |
| Principal investigator 1 | Alkermes, Inc. | $1,250.00 | 06/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618559 |
| Principal investigator 1 | Alkermes, Inc. | $3,584.00 | 06/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619383 |
| Principal investigator 1 | Alkermes, Inc. | $5,504.00 | 06/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619981 |
| Principal investigator 1 | Alkermes, Inc. | $3,200.00 | 06/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623404 |
| Principal investigator 1 | Alkermes, Inc. | $3,840.00 | 06/04/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626020 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613727 |
| Principal investigator 1 | Alkermes, Inc. | $3,114.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208614609 |
| Principal investigator 1 | Alkermes, Inc. | $5,751.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615075 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615635 |
| Principal investigator 1 | Alkermes, Inc. | $5,751.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615637 |
| Principal investigator 1 | Alkermes, Inc. | $5,949.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616077 |
| Principal investigator 1 | Alkermes, Inc. | $5,153.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617157 |
| Principal investigator 1 | Alkermes, Inc. | $5,949.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617389 |
| Principal investigator 1 | Alkermes, Inc. | $3,165.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618009 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618011 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618521 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618967 |
| Principal investigator 1 | Alkermes, Inc. | $3,246.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618971 |
| Principal investigator 1 | Alkermes, Inc. | $758.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619225 |
| Principal investigator 1 | Alkermes, Inc. | $6,118.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619451 |
| Principal investigator 1 | Alkermes, Inc. | $5,153.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619709 |
| Principal investigator 1 | Alkermes, Inc. | $5,947.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619711 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619941 |
| Principal investigator 1 | Alkermes, Inc. | $6,118.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620165 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620387 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622529 |
| Principal investigator 1 | Alkermes, Inc. | $3,246.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622733 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622970 |
| Principal investigator 1 | Alkermes, Inc. | $5,751.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623662 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623870 |
| Principal investigator 1 | Alkermes, Inc. | $5,153.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624766 |
| Principal investigator 1 | Alkermes, Inc. | $3,246.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625678 |
| Principal investigator 1 | Alkermes, Inc. | $1,492.00 | 06/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626300 |
| Principal investigator 1 | Alkermes, Inc. | $578.06 | 05/27/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621935 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,728.00 | 05/23/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737579 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $384.00 | 05/23/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737585 |
| Principal investigator 1 | Alkermes, Inc. | $716.34 | 05/19/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622357 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $93,108.46 | 05/14/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223279760 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,188.18 | 05/14/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223279778 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,585.92 | 05/09/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223279384 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 05/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613926 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 05/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615061 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 05/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615063 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 05/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617555 |
| Principal investigator 1 | Alkermes, Inc. | $4,244.00 | 05/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617557 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 05/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621428 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 05/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622143 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 05/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622713 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 05/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623184 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 05/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623652 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 05/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625425 |
| Principal investigator 1 | Alkermes, Inc. | $51.40 | 05/05/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616429 |
| Principal investigator 1 | Alkermes, Inc. | $1.71 | 05/05/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621356 |
| Principal investigator 1 | Alkermes, Inc. | $176.00 | 05/05/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625097 |
| Principal investigator 1 | Alkermes, Inc. | $15.39 | 05/05/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626826 |
| Principal investigator 1 | Alkermes, Inc. | $1,045.00 | 05/01/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615261 |
| Principal investigator 1 | Alkermes, Inc. | $1,770.00 | 04/30/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616241 |
| Principal investigator 1 | Alkermes, Inc. | $1,770.00 | 04/30/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623388 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20,695.97 | 04/18/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223278516 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $151,054.00 | 04/09/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737575 |
| Principal investigator 1 | Alkermes, Inc. | $3,201.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613101 |
| Principal investigator 1 | Alkermes, Inc. | $5,947.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613307 |
| Principal investigator 1 | Alkermes, Inc. | $1,492.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613513 |
| Principal investigator 1 | Alkermes, Inc. | $5,949.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615189 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615799 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615891 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616025 |
| Principal investigator 1 | Alkermes, Inc. | $4,600.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616495 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618185 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618689 |
| Principal investigator 1 | Alkermes, Inc. | $5,751.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618907 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619643 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619953 |
| Principal investigator 1 | Alkermes, Inc. | $3,201.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621658 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622309 |
| Principal investigator 1 | Alkermes, Inc. | $6,118.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623136 |
| Principal investigator 1 | Alkermes, Inc. | $3,246.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624114 |
| Principal investigator 1 | Alkermes, Inc. | $3,114.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624987 |
| Principal investigator 1 | Alkermes, Inc. | $5,153.00 | 04/07/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626648 |
| Principal investigator 1 | Alkermes, Inc. | $56.85 | 04/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613625 |
| Principal investigator 1 | Alkermes, Inc. | $113.34 | 04/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617077 |
| Principal investigator 1 | Alkermes, Inc. | $77.64 | 04/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617679 |
| Principal investigator 1 | Alkermes, Inc. | $52.48 | 04/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617889 |
| Principal investigator 1 | Alkermes, Inc. | $115.65 | 04/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620087 |
| Principal investigator 1 | Alkermes, Inc. | $228.53 | 04/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622631 |
| Principal investigator 1 | Alkermes, Inc. | $259.54 | 04/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622639 |
| Principal investigator 1 | Alkermes, Inc. | $82.08 | 04/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625824 |
| Principal investigator 1 | Alkermes, Inc. | $119.36 | 04/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626622 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,514.24 | 04/02/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737583 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $64,707.84 | 04/02/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223277558 |
| Principal investigator 1 | Eisai Inc. | $22,254.08 | 03/27/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | Lemborexant in Delayed Sleep Phase Syndrome | No dispute reported | 06/30/2026 | 1244561342 |
| Principal investigator 1 | Alkermes, Inc. | $3,201.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613639 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613856 |
| Principal investigator 1 | Alkermes, Inc. | $5,947.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208614531 |
| Principal investigator 1 | Alkermes, Inc. | $3,246.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615185 |
| Principal investigator 1 | Alkermes, Inc. | $5,153.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616011 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616661 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616663 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618427 |
| Principal investigator 1 | Alkermes, Inc. | $5,751.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618891 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619139 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619627 |
| Principal investigator 1 | Alkermes, Inc. | $4,600.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622880 |
| Principal investigator 1 | Alkermes, Inc. | $685.00 | 03/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624905 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $156,320.00 | 03/05/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269224 |
| Principal investigator 1 | Alkermes, Inc. | $128.50 | 03/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616729 |
| Principal investigator 1 | Alkermes, Inc. | $132.00 | 03/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617577 |
| Principal investigator 1 | Alkermes, Inc. | $77.10 | 03/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624354 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 03/03/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626954 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,207.36 | 03/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737517 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,428.16 | 03/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737539 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $9,308.16 | 03/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737551 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $42.00 | 02/28/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744341 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $35.00 | 02/28/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744347 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $55.00 | 02/28/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744349 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $55.00 | 02/28/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744351 |
| Principal investigator 1 | Eisai Inc. | $256.00 | 02/26/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | Lemborexant in Delayed Sleep Phase Syndrome | No dispute reported | 06/30/2026 | 1244561336 |
| Principal investigator 1 | Eisai Inc. | $1,638.00 | 02/26/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | Lemborexant in Delayed Sleep Phase Syndrome | No dispute reported | 06/30/2026 | 1244561340 |
| Principal investigator 1 | Eisai Inc. | $16,690.56 | 02/26/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | Lemborexant in Delayed Sleep Phase Syndrome | No dispute reported | 06/30/2026 | 1244561344 |
| Principal investigator 1 | Alkermes, Inc. | $5,153.00 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615355 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616315 |
| Principal investigator 1 | Alkermes, Inc. | $15.39 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616331 |
| Principal investigator 1 | Alkermes, Inc. | $218.45 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618945 |
| Principal investigator 1 | Alkermes, Inc. | $5,489.00 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619841 |
| Principal investigator 1 | Alkermes, Inc. | $16.00 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619949 |
| Principal investigator 1 | Alkermes, Inc. | $412.40 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620181 |
| Principal investigator 1 | Alkermes, Inc. | $3,217.00 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620744 |
| Principal investigator 1 | Alkermes, Inc. | $162.05 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621452 |
| Principal investigator 1 | Alkermes, Inc. | $100.30 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621891 |
| Principal investigator 1 | Alkermes, Inc. | $22.50 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623862 |
| Principal investigator 1 | Alkermes, Inc. | $5,751.00 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624028 |
| Principal investigator 1 | Alkermes, Inc. | $47.75 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624110 |
| Principal investigator 1 | Alkermes, Inc. | $70.40 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624338 |
| Principal investigator 1 | Alkermes, Inc. | $1.71 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624556 |
| Principal investigator 1 | Alkermes, Inc. | $3,246.00 | 02/12/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625599 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5,664.13 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737505 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $26.88 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737511 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,428.16 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737515 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $125.44 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737519 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,548.48 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737521 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,538.56 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737527 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,401.60 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737535 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,008.32 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737545 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,590.72 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737547 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,008.32 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737559 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,538.56 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737561 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,523.12 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737565 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,428.16 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737567 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,312.00 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737569 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,590.72 | 02/03/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737571 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $55,887.36 | 02/03/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269204 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $21,261.00 | 02/03/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269206 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,040.00 | 02/03/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269208 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,840.00 | 02/03/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269210 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,584.00 | 02/03/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269212 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,496.00 | 02/03/2025 | Covered Recipient Teaching Hospital STANFORD HEALTH CARE | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223269214 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $55.00 | 01/31/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744339 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $55.00 | 01/31/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744343 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $42.00 | 01/31/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744345 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $35.00 | 01/31/2025 | Non-covered Recipient Entity Stanford University Division of Sleep Medicine | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744353 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,200.00 | 01/22/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737503 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $407.00 | 01/22/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737529 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,500.00 | 01/22/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737533 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $4,620.00 | 01/22/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737537 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $384.00 | 01/22/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737549 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $49.92 | 01/22/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737563 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,780.42 | 01/22/2025 | Covered Recipient Teaching Hospital BOARD OF TRUSTEES OF THE UNIVERSITY | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223264286 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6,531.84 | 01/17/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737507 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,688.00 | 01/17/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737509 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,824.00 | 01/17/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737513 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,116.16 | 01/17/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737523 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,548.48 | 01/17/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737525 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6,575.36 | 01/17/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737531 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6,575.36 | 01/17/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737541 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,824.00 | 01/17/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737543 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,401.60 | 01/17/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737553 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,078.52 | 01/17/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737555 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $4,857.60 | 01/17/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737557 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,688.00 | 01/17/2025 | Non-covered Recipient Entity Board of Trustees of the Leland Stanford Junior University | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737573 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $992.00 | 01/10/2025 | Covered Recipient Physician | A DOSE-BLIND EXTENSION STUDY WITH DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND EXPLORE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-994 IN ADULTS WITH NARCOLEPSY WITH CATAPLEXY (NARCOLEPSY TYPE 1) | No dispute reported | 06/30/2026 | 1223263202 |
| Principal investigator 1 | Alkermes, Inc. | $15,156.91 | 01/01/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208627094 |
| Principal investigator 1 | Alkermes, Inc. | $10,678.47 | 01/01/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208627172 |
| Principal investigator 1 | Alkermes, Inc. | $16,536.51 | 01/01/2025 | Non-covered Recipient Entity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208627242 |